2056, 2056-f, 2056-b, 2054, 2054-f, 2054-b (2S) and (2R), aka DMT, Tyr(2,6-dimethyl), 2S- or 2R-Amino-3-(4-hydroxy, 2,6-dimehtylphenyl)propanoic acid, 26DMY or 26DMy
RSP introduced 2,6-dimethyltyrosine commercially for pre-clinical research at the IRCM in Canada in 2000. It is active in organic synthesis for medicinal chemistry, pain, and cardiovascular research boosting respiration in heart tissue. We offer 2,6-dimethyltyrosine in the purest form (99+%, 99+% ee 2S, less than 0.5% 2R, measured 0.25%) available. The FDA thinks this is important because formula toxicity has been attributed to enantiomeric impurities. For this reason, we went on to develop and distribute the purest fom of the opposite enantiomer (2R-isomer, 2054) so that research can examine its effect in their drug leads. Our customers use our material in clinical studies because a less than a 0.5% impurity of the opposite enantiomer can destroy their program in animal and human studies. The hallmark of chiral medicine is potency, therefore you must rule out toxic effects as proof for approval.
The product is available from grams to kilograms or larger at these specifications. This molecule of the week has a 20% discount for the next 30 days (6/15/2016). Contact us for a quote, to modify it chemically or to build it into your drug candidate. We are highly skilled at incorporaton of our analogues as terminnal caps, in sequence with normal or modified backbones, in linear, cyclic peptides and peptidomimetics.
1. Schiller PW. "Bi- or multifunctional opioid peptide drugs." Life Sci. 2010;86:598–603.
2. Szeto, H. et. al. "Mitochondrial Targeting with Antioxidant Peptide SS-31 Prevents Mitochondrial Depolarization, Reduces Islet Cell Apoptosis, Increases Islet Cell Yield, and Improves Posttransplantation Function." Department of Medicine, Cornell University, Итак, New York, United States, Journal of the American Society of Nephrology (Impact Factor: 9.34). 01/2007; 18(1):213-22.
3. Hruby, V.J. et. al. "Opioid and Melanocortin Receptors: Do They Have Opioid Overlapping Pharmacophores?" Biopolymers. 2008; 90(3): 433–438.
4. Armishaw, C.J., et. al. The Journal of Biological Chemistry, 285, 1809-1821 (2010).
5. Okada, Y. 'Design and synthesis of opioidmimetics containing 2 ',6 '-dimethyl-L-tyrosine and a pyrazinone-ring platform" Bioorganic & Medicinal Chemistry Letters 17(21):5768-71 · November 2007
6. Hoye, Adam T, et. al. Targeting Mitochondria, Accounts of chemical research, 41 (1). pp. 87-97. ISSN 1520-4898
7. Cai, C. A convenient, "larg-scale systhesis of 4'-carboxamido N-Boc-2,6-dimethyl-L-phenylalanines," Tetrahedron 61 (2005) 6836-6838.
8. Lawrence H. Lazarus, et. al. "Role of 2′,6′-Dimethyl-L-Tyrosine (Dmt) in Some Opioid Lead Compounds" Bioorg Med Chem. 2010 Aug 15; 18(16): 6024–6030.Studies on the structure–activity relationship of 2′,6′-dimethyl-l-tyrosine (Dmt) derivatives: bioactivity profile of H–Dmt–NH–CH3,"
9. Yoshio Fujita, et. al. "Studies on the structure–activity relationship of 2′,6′-dimethyl-l-tyrosine (Dmt) derivatives: bioactivity profile of H–Dmt–NH–CH3." Bioorganic & Medicinal Chemistry Letters, Volume 15, Issue 3, 1 February 2005, Pages 599–602.
10. Gregory L Verdine, et. al. "2,6-Dimethyltyrosine Analogues of a Stereodiversified Ligand Library: Highly Potent, Selective, Non-Peptidic μ Opioid Receptor Agonists." Journal of Medicinal Chemistry (Impact Factor: 5.45). 03/2003; 46(5):677-80.
11. Jane V. Aldrich, et. al. "Opioid Peptides: Potential for Drug Development" Drug Discov Today Technol. 2012; 9(1): e23–e3112. Peter W. Schiller, et. al. "Novel Opioid Peptide Derived Antagonists Containing (2S)-2-Methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic Acid [(2S)-Mdcp]." J Med Chem. 2008 Sep 25; 51(18): 5866–5870.
13. Victor J. Hruby, et. al. "Antinociceptive Activity of [β-Methyl-2′,6′-dimethyltyrosine1]-Substituted Cyclic [d-Pen2,d-Pen5]Enkephalin and [d-Ala2,Asp4]Deltorphin Analogs." JPET April 1, 2000 vol. 293 no. 1 151-158.
14. Janecka A, et al. Development of opioid peptide analogs for pain relief. Curr Pharm Des. 2010;16:1126–1135
15. Schiller P, et. al. "Comparison of[Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.J Pharmacol Exp Ther 307: 947–954, 2003
16. Brown DA, et. al. "Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia." J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):121-32.
17. Dolle, R.E., Hipkin, R.W. " Opoid Receptor Antagonists for Gastrointestinal Dysfunction" Annual Reports In Medicinal Chemistry, V45, p143 (2010).
